UAB Hematology Review 2021

 

Videos
09:00

UAB Hematology Review 2021

Sickle Cell Disease in Clinical Practice: Pathophysiology, Mortality, HU Therapy, L-Glutamine, Blood Transfusion, Alloimmunization, Iron Overload

FEATURING Julie Kanter
  • 54 views
  • March 22, 2021
08:14

UAB Hematology Review 2021

New Therapies for Sickle Cell Disease in 2021: Crizanlizumab vs. Placebo, Voxelotor+Placebo, Identifying Appropriate Treatment

FEATURING Julie Kanter
  • 293 views
  • March 22, 2021
  • 1
13:34

UAB Hematology Review 2021

CLL Management in Times of COVID-19: Frontline Acalabrutinib or Ven +/- Obi, Ibrutinib, How to Identify Barriers to Treatment Due to the Ongoing Pandemic?

FEATURING Mayur Narkhede
  • 108 views
  • March 18, 2021
20:13

UAB Hematology Review 2021

Advanced Stage cHL: Considering Frontline, Secondary, and Salvage Treatment Choices and Navigating End of Treatment PET and PET2+ Patients

FEATURING Gaurav Goyal
  • 37 views
  • March 18, 2021
37:07

UAB Hematology Review 2021

Hematopathology Pearls for Clinicians: Danger of “Preliminary Diagnosis”, FNA vs. Core vs. Excisional Biopsy, TAT Factors, Flow Cytometry, NGS

FEATURING Diana Morlote
  • 146 views
  • March 18, 2021
  • 1
18:42

UAB Hematology Review 2021

2021 Updates on the Use of DOACs: Which GI/GU Patients Are Suitable Candidates? Are DOACs Recommended for Obese Patients? Is Rivaroxaban Beneficial for Arterial Thrombosis?

FEATURING Jori May
  • 28 views
  • March 18, 2021
21:42

UAB Hematology Review 2021

Hematologic Manifestations of COVID-19: Thrombosis Mechanisms and Risk, COVID-19 Associated Coagulopathy, Anticoagulation Recommendations, Post-Discharge Prophylaxis

FEATURING Radhika Gangaraju
  • 3,638 views
  • March 18, 2021
  • 16
15:39

UAB Hematology Review 2021

2021 Updates on 2L CML and Beyond: TKIs (Imatinib, Dasatinib/Nilotinib/Bosutinib Continuation, Ponatinib), Omacetaxine, Asciminib, HQP1351

FEATURING Omer Jamy
  • 208 views
  • March 18, 2021
  • 1
24:58

UAB Hematology Review 2021

Interferon for PV: Types, MOA, Effects in MPN, Pegylation of IFN, PEG vs. HU for High-Risk Disease, IFN Alfa-2 vs. HU, PEG-IFN Alfa-2b

FEATURING Pankit Vachhani
  • 360 views
  • March 18, 2021
  • 3
24:01

UAB Hematology Review 2021

2021 UAB Updates on Relapsed DLBCL: Salvage Chemo+ASCT, Len+Rituximab, Bendamustine+Rituximab+Polatuzumab, Tafasitamab+Len, Selinexor, CAR-T

FEATURING Amitkumar Mehta
  • 217 views
  • March 18, 2021
23:44

UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Summary for Triple Refractory Disease

FEATURING Kelly Godby
  • 313 views
  • March 16, 2021
  • 2
17:39

UAB Hematology Review 2021

Incorporating MoAbs in Frontline Treatment of MM: Assessing the Data From MAIA and GRIFFIN Studies

FEATURING Smith Giri
  • 216 views
  • March 16, 2021
14:06

UAB Hematology Review 2021

Frontline Daratumumab in MM: D-VTd vs. VTd, D-RVd vs. RVd in Transplant-Eligible Disease, Dara-KRd; Dara+/-VMP, Dara+Len/Dex vs. Len Alone in Transplant-Ineligible Disease

FEATURING Susan Bal
  • 97 views
  • March 16, 2021
  • 1
23:19

UAB Hematology Review 2021

Clinical Pearls: 2021 Review of Recently Approved Agents in Hematology

FEATURING Sarah Worth
  • 65 views
  • March 16, 2021
15:48

UAB Hematology Review 2021

UAB 2021 Updates on Frontline MDS: Can We Achieve AUC Decitabine at 5 Days? NTX-301, Aza+Ven, Aza+Magrolimab

FEATURING Kimo Bachiashvili
  • 69 views
  • March 16, 2021